呼吸器感染症におけるgrepafloxacinの効果および喀痰中の薬動力学的検討

DOI 参考文献5件

書誌事項

タイトル別名
  • Clinical efficacy of grepafloxacin in respiratory infections and its pharmacokinetics in sputum

この論文をさがす

抄録

We evaluated the clinical efficacy and safety of grepafloxacin (GPFX) in a phase 2 study in a total of seven patients with respiratory infections. GPFX was administered orally at a dose of 150 to 300mg daily. The time course of the serum and sputum concentrations was evaluated after administering a 300mg dose to one patient, and pharmacokinetic analysis was also performed. The subjects included one case each of bronchial asthma and diffuse panbronchiolitis, and five cases of bronchiectasis. Clinical response was good in three cases, fair in one and poor in two. Two strains of Haemophilus influenzae were eradicated, while three strains of Pseudomonas aeruginosa persisted in spite of their susceptibility to GPFX. One patient had headache and lumbago as well as chest discomfort four hours after taking GPFX. No abnormal laboratory findings were observed.<BR>The peak concentration of GPFX in sputum (four hours after administration) was 2.31μg/ml, almost two-fold that in serum, suggesting its efficacy in respiratory infections.

収録刊行物

参考文献 (5)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ